A New Era in Medicine
Written By: Keith Kohl
Posted: Sep 9, 2016
Jonas Salk could have ruled the world.
In case the story behind the name has slipped your mind, Salk was the creator of the vaccine for polio. You'll note that the once-rampant disease has been wiped out since then.
Salk never monetized his discovery. In fact, when asked about a patent on the vaccine, he's said to have replied, “There is no patent. Could you patent the sun?”
He seemed content to become the “miracle worker” that saved the world. But if he had patented his creation, he'd have died rolling in profits.
Just two years after the vaccine was released to the public, the value of Salk and his vaccine would have mirrored real-life bio-medical company gains like:
And given the importance of the discovery, it's likely that the one and only cure for polio would have easily beaten these profits.
Today's Polio Vaccine
Imagine for a moment that you could go back and patent that vaccine yourself. How rich do you think you could be today?
Dear reader, I've got some good news for you: my colleague Christian DeHaemer has found a stock poised to offer not only a much better opportunity for change, but a much higher reward as well.
After all, Salk only cured polio...
The technology this company is working on could cure today's two biggest killers: cancer and heart disease.
These deadly ailments have ended more lives than car wrecks, suicides, gun violence, or war... They take the life of one in four infected people every single day.
They're sneaky and often silent until it's too late. When we do catch them, they can be almost impossible to get rid of.
But this technology could change all that.
It's today's polio vaccine, but 100% bigger and more life saving than any medicine on the market before or since.
And the best part is that it's not a new invention, but something that already exists: stem cells.
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the newsletter below.
Stem cells are basically blank biological pages on which a clean set of directions can be written. They can be made to become any other cell in a living human body; heck, they come from human bodies to begin with!
The breakthrough isn't actually in the creation of these cells, but in how to control them.
These little buggers can actually harm the host body if they're not treated correctly. This makes for a much bigger problem, as you can well imagine.
But one company has found the key... the secret to making stem cells work for the body, not against it.
And nothing against Jonas Salk, but we're not about to let an opportunity like this pass us by without a little cash trading hands.
Right now, this quiet little company is trading under the radar for just a couple of dollars. But it's projected to shoot upward at least 300% within the next two years!
The stem cell market alone is expected to more than double by 2020, which will open the door to tons of new investment opportunities. Unfortunately, you'll only get the chance to invest in the ground floor of this market once.
Look, this isn't some teenage romance novel, serial killer series, or TV show where the sickness is solved and gone forever in an hour... this is real life.
More importantly, this technology will have real consequences, and investors today will be making real gains.
But just as our killers number their victims' days, you too have a time limit on taking us up on this deal of a lifetime. After all, this kind of development just can't wait around for you to decide!
Until next time,
A true insider in the energy markets, Keith is one of few financial reporters to have visited the Alberta oil sands. His research has helped thousands of investors capitalize from the rapidly changing face of energy. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital as well as Investment Director of Angel Publishing's Energy Investor. For years, Keith has been providing in-depth coverage of the Bakken, the Haynesville Shale, and the Marcellus natural gas formations — all ahead of the mainstream media. For more on Keith, go to his editor's page.